Ireland
--:--IST
Recruiting Not applicable

Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.

NCT06949579 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-02-12
Last updated
2026-08-07

Condition(s) studied

High Myopia

Investigational drug(s) / intervention(s)

blood sampling for DNA

blood sampling for DNA: Blood sampling for DNA and serum and plasma colection and PBMC

Study summary

In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included.

600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset.

Besides the standard of care, blood samples will be collected.

All data collected will be stored in an onlie Castor database

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma * Adults aged 18 years or over * Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging * Patient who has signed a consent form to participate in the study * Patient who is a beneficiary of a social security scheme or who is entitled to it Exclusion Criteria: * Any systemic or ocular pathologies with an impact on the posterior segment of the eye * Patient with a systemic pathology likely to affect the posterior segment of the eye: * Diabetes * Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease * Patients with retinitis pigmentosa * Patients with syndromic myopia * Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy * Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP).

Primary outcome measure(s)

  • Differential gene expression between myopic patients with and without staphyloma — Through study completion, an average of 1 year.
    Genetic analysis

Trial sites (1)

FacilityCityRegionStatus
Cochin Hospital Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06949579 on ClinicalTrials.gov ↗ ← All trials in France